

Pharmacia & Upjohn

Agent ID# 29294

MITABAN[®] Liquid Concentrate MATERIAL SAFETY DATA SHEET

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

COMMON NAME: MITABAN[®] Liquid Concentrate

SYNONYMS: 402839 – EDP Number

MOLECULAR FORMULA: Mixture

CHEMICAL FAMILY: Mixture

USE: Veterinary product indicated for the treatment of generalized demodicosis (*Demodex canis*) in dogs. Not for human use.

MANUFACTURER/SUPPLIER:

PHARMACIA & UPJOHN CO., A SUBSIDIARY OF
PHARMACIA CORP.

7171 PORTAGE RD

KALAMAZOO, MI 49001-0199

TELEPHONE NUMBERS:

(616) 833-5122 - (24 Hours)

(616) 833-7555 - (8:00 AM - 4:30 PM, EST)

2. COMPOSITION/INFORMATION ON INGREDIENTS

INGREDIENT 1

COMMON NAME: Xylene (o-, m-, p- isomers)

% BY WEIGHT: 74.5 %

CAS NUMBER: 1330-20-7

EXPOSURE LIMIT(S): OSHA PEL-TWA: 100 PPM

OSHA PEL-STEL: 150 PPM

ACGIH TLV-TWA: 100 PPM

ACGIH TLV-STEL: 150 PPM

INGREDIENT 2

COMMON NAME: Amitraz

CHEMICAL NAME: Methanimidamide, N' -(2,4-dimethylphenyl)-N-[[[(2,4-dimethylphenyl)imino]methyl]-N-m-ethyl-

% BY WEIGHT: 21% to 24%

CAS NUMBER: 33089-61-1

EXPOSURE LIMIT(S): Not established.

INGREDIENT 3

COMMON NAME: Propylene Oxide

% BY WEIGHT: 1 %

CAS NUMBER: 75-56-9

EXPOSURE LIMIT(S): OSHA PEL-TWA: 20 PPM

OSHA PEL-TWA (Transitional limit): 100 PPM

ACGIH TLV-TWA: 20 PPM

EXPOSURE LIMIT(S) FOR THE MATERIAL: Not established.

3. HAZARDS IDENTIFICATION

PRIMARY ROUTE(S) OF EXPOSURE: Skin contact, eye contact, ingestion, and inhalation.

EFFECTS OF OVEREXPOSURE: Ingestion may cause hyperglycemia, hypothermia and/or central nervous system depression. Inhalation may cause central nervous system depression, nasal discharge and/or dyspnea. Prolonged skin contact may lead to irritation, dermatitis and/or allergic reactions. Contact with haircoats of dogs within several days post-treatment may lead to skin reactions, especially in children. Skin absorption may result in systemic effects. Eye contact may lead to conjunctival irritation, iritis and corneal opacity, and can be corrosive.

4. FIRST AID MEASURES

EYES: Rinse immediately with water for 15 minutes; call a physician immediately.

SKIN: Wash with soap and water; remove contaminated clothing and shoes. Consult a physician.

INHALATION: Remove person from further exposure.

INGESTION: Do not induce vomiting. Call a physician immediately.

NOTES TO PHYSICIAN: MITABAN is a mixture of amitraz, propylene oxide and xylene. The time of onset and duration of symptoms from accidental overexposure has not been determined. Sedation has been seen in dogs from 2 to 6 hours post-treatment with dissipation occurring in 24 to 72 hours. MITABAN and its components are known to be absorbed through the skin. Chronic overexposure may lead to altered homeostasis and target organ damage; including central nervous system depression and liver damage due to xylene. There is no known antidote for MITABAN or its components. The product is packaged in 10.6-mL vials. Medical management for ingested MITABAN is gastric lavage. Induction of vomiting may be contraindicated because the product contains xylene and emesis risks entry of stomach contents into the respiratory tract. Subsequent treatment is symptomatic and supportive. There is experimental evidence that systemic effects resulting from ingestion are not ameliorated by absorption retardants, specific antidote therapy, induction of diuresis or modification of urine pH. In most circumstances, the chemical should be removed from the stomach if the amount is large (several ounces). Removal is indicated if the chemical is a carrier for a more toxic substance such as a pesticide. If gastric lavage is carried out, it should use the largest practical nasogastric or orogastric tube, with a cuffed endotracheal tube in place. Follow the above with an activated charcoal slurry: adult dose is 50 to 100 g; pediatric 30 to 50 g. Follow the above by administering a cathartic such as magnesium sulfate (adults: 30 g or 300 cc of 10% solution; pediatric: 250 mg/kg) or magnesium citrate. Cathartics alone may suffice for small ingestions. General supportive measures should be used, as indicated.

5. FIRE FIGHTING MEASURES

FLASH POINT: 13° C (55° F) (flammable liquid)

Pharmacia & Upjohn

Agent ID# 29294

MITABAN[®] Liquid Concentrate MATERIAL SAFETY DATA SHEET

LOWER EXPLOSION LIMIT (LEL): Not applicable.
UPPER EXPLOSION LIMIT (UEL): Not applicable.
EXTINGUISHING MEDIA: Foam, carbon dioxide or dry chemical.

FIRE FIGHTING PROCEDURES: Wear self-contained breathing apparatus and full-body protective equipment.

UNUSUAL FIRE OR EXPLOSION HAZARDS: Severe in the form of vapor when exposed to heat or flame.

HAZARDOUS COMBUSTION PRODUCTS: Carbon monoxide. Carbon dioxide. Nitrogen oxides.

6. ACCIDENTAL RELEASE MEASURES

STEPS TO BE TAKEN IN CASE MATERIAL IS RELEASED OR SPILLED: Absorb large spills with appropriate absorbents. Remove container to safe place where leakage can be stopped. Shut off all sources of potential ignition. Extinguish all flames.

7. HANDLING AND STORAGE

PRECAUTIONS FOR HANDLING AND STORING:
The handling precautions specified are recommended when handling and application of formulated products. Read the product label for precautionary statements and directions for use. Keep out of reach of children. Harmful or fatal if swallowed. Do not store near food or feed. This product is toxic to fish. Keep out of lakes, ponds or streams. Causes eye and skin irritation. Do not get in eyes, on skin or on clothing. Wear rubber gloves and protective clothing when handling. Avoid breathing vapors or spray mist. Do not contaminate water by cleaning of equipment or disposal of wastes. Wash thoroughly after handling. Keep container closed. Do not reuse container.

8. EXPOSURE CONTROLS/ PERSONAL PROTECTION

RESPIRATORY PROTECTION: Recommended during prolonged or repeated use during the work day.

VENTILATION: Local exhaust.

PROTECTIVE GLOVES: Resistant to aromatic solvents (i.e., polyethene).

EYE PROTECTION: Safety glasses with side shields.

OTHER PROTECTIVE EQUIPMENT: Protective covering for exposed areas of skin. Wear clean clothing each day and launder before reusing. Use non-sparking tools and equipment.

9. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE/PHYSICAL STATE: Pale, amber-brown liquid.

MELTING POINT: Not applicable.

MOLECULAR WEIGHT: Mixture.

ODOR: Aromatic smell of xylene.

SOLUBILITY IN WATER: Insoluble.

10. STABILITY AND REACTIVITY

STABILITY: Conditions contributing to instability: direct flame.

PHYSICAL CONDITIONS TO AVOID: None.

INCOMPATIBILITY WITH OTHER MATERIALS:
Oxidizing agents.

HAZARDOUS DECOMPOSITION PRODUCTS: Vapors may be toxic.

HAZARDOUS POLYMERIZATION: Does not occur.

11. TOXICOLOGICAL INFORMATION

ACUTE STUDIES:

SKIN LD50 (MOUSE): 71 g/kg

INHALATION LC50 (RAT): >2.3 mg/L

ORAL LD50 (MOUSE): 1,500 mg/kg

OTHER STUDIES:

CARCINOGENICITY: MITABAN is not listed as a carcinogen by IARC, NTP or OSHA. Amitraz, the active ingredient in MITABAN, has been designated as a group C carcinogen by EPA on the basis of induction of liver tumors in female mice at doses exceeding the MTD. Possibly carcinogenic for humans based on limited animal evidence in the absence of human data.

12. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHOD: Dispose of by incineration in accordance with applicable international, national, state and/or local waste disposal regulations.

13. SHIPPING REGULATIONS

PROPER SHIPPING NAME: Consumer commodity.

HAZARD CLASS: ORM-D.

14. OTHER INFORMATION

REVIEWED BY: Environment & Safety.

DISCLAIMER: The information contained in the MSDS is believed to be correct as of its date of issuance. BY MAKING THE MSDS AVAILABLE, PHARMACIA & UPJOHN CO. DOES NOT MAKE ANY EXPRESS OR IMPLIED WARRANTY (INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE) REGARDING THE MSDS, ITS ACCURACY OR THE PRODUCT TO WHICH IT RELATES. Anyone using this information

Pharmacia & Upjohn

Agent ID# 29294

MITABAN[®] Liquid Concentrate
MATERIAL SAFETY DATA SHEET

agrees that Pharmacia & Upjohn shall not be held liable (based on its negligence or otherwise) for any personal injury or other damage relating to, or arising from such use, including direct, incidental, or consequential damage and such user agrees to indemnify Pharmacia & Upjohn for any claims arising out of its use.

15. LABELING

This drug is subject to FDA labeling requirements; therefore, it is exempt from the labeling requirements of the OSHA Hazard Communication Standard.

NDC 0009-3118-01

July 31, 2001